You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer
|
---|---|
Published in |
Molecular Cancer, September 2013
|
DOI | 10.1186/1476-4598-12-104 |
Pubmed ID | |
Authors |
Kolaparthi Venkatasubbarao, Lindsay Peterson, Shujie Zhao, Ping Hill, Lin Cao, Qing Zhou, Steffan T Nawrocki, James W Freeman |
Abstract |
Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis. Gemcitabine is the standard first line of therapy for pancreatic cancer but has limited efficacy due to inherent or rapid development of resistance and combining EGFR inhibitors with this regimen results in only a modest clinical benefit. The goal of this study was to identify molecular targets that are activated during gemcitabine therapy alone or in combination with an EGFR inhibitor. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Hungary | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 26% |
Other | 6 | 17% |
Student > Ph. D. Student | 4 | 11% |
Student > Master | 3 | 9% |
Student > Bachelor | 2 | 6% |
Other | 6 | 17% |
Unknown | 5 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 9 | 26% |
Medicine and Dentistry | 9 | 26% |
Biochemistry, Genetics and Molecular Biology | 8 | 23% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Computer Science | 1 | 3% |
Other | 3 | 9% |
Unknown | 3 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2013.
All research outputs
#16,849,988
of 25,559,053 outputs
Outputs from Molecular Cancer
#1,166
of 1,936 outputs
Outputs of similar age
#128,234
of 211,158 outputs
Outputs of similar age from Molecular Cancer
#16
of 24 outputs
Altmetric has tracked 25,559,053 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,936 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,158 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.